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Background
There are no standardized criteria or protocol for the
withdrawal of inhaled corticosteroids (ICS) from
remitted pediatric asthma in Japanese Pediatric Guide-
line for the Treatment and Management of Asthma
(JPGL).
Methods
Among 55 asthmatic subjects in our hospital, FeNO and
pulmonary functions were measured at the withdrawal
of ICS, at 1 month and 3 month after. Those data were
investigated whether it would be a predictor for the
recurrence of asthma symptoms.
Results
Subjects in recurrent asthma symptom group were 28
cases and those of non-recurrent asthma symptom group
27 cases (relapse rate: 50.9%). Any significant factors in
background patients’ profiles, such as FeNO and pulmon-
ary functions, were not associated with the recurrence of
asthma. In recurrent asthma symptom group, FeNO was
significantly increased by 3 months after withdrawal of
ICS (from 31.8 ppb to 49.2 ppb). Among recurrent asthma
symptom group, pulmonary functions were significantly
decreased within 1 months (FVC: from 2.11L to 2.02L,
FEV1.0: from 1.93L to 1.85L and %FEV1.0: from 98.1% of
to 93.8%).
Conclusions
Although these factors at the time of ICS withdrawal
could not predict asthmatic revival, it is highly recom-
mended to follow asthmatic patients who quit ICS ther-
apy by measuring pulmonary function and FeNO
periodically.
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